Lupin Receives EIR from US FDA for Goa Facility
Key Takeaways
Mumbai, February 27, 2026: Indian pharmaceutical giant Lupin Limited has announced that its manufacturing facility in Goa has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA). The facility was granted a Voluntary Action Indicated (VAI) classification following an inspection conducted between November 10 and November 21, 2025.
Nilesh Gupta, Managing Director of Lupin, expressed the company’s satisfaction with the results of the inspection. "We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide", he stated.
The VAI classification indicates that while some issues may have been identified during the inspection, they do not warrant regulatory or enforcement action. This outcome underscores Lupin's dedication to maintaining high standards of quality and compliance in its operations.
About Lupin
Lupin Limited, headquartered in Mumbai, India, is a global leader in the pharmaceutical industry with products distributed in over 100 markets. The company specializes in a wide range of pharmaceutical solutions, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Its therapeutic focus spans multiple areas, such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.
With a network of 15 manufacturing facilities and 7 research centers worldwide, Lupin is supported by a workforce of over 24,000 professionals. The company remains committed to improving patient health outcomes through its subsidiaries, which include Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
This latest development highlights Lupin’s ongoing efforts to ensure regulatory compliance while delivering high-quality pharmaceutical products to patients around the world.
Author
